News Search Results
Nov 11, 2025, 09:00 ET Lexogen honored as one of Austria's Top Innovative Companies 2026 by Statista and trend. magazine
them international renown. About Lexogen Lexogen is a biotechnology company specialized in RNA sequencing, which engineers, produces, and delivers innovative solutions for studying genes and how they are expressed
More news about: LEXOGEN
Nov 11, 2025, 09:00 ET Lexogen honored as one of Austria's Top Innovative Companies 2026 by Statista and trend. magazine
them international renown. About Lexogen Lexogen is a biotechnology company specialized in RNA sequencing, which engineers, produces, and delivers innovative solutions for studying genes and how they are expressed
More news about: LEXOGEN
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- iLeukon Therapeutics, Inc., a San Diego-based clinical-stage biotechnology company developing next-generation mRNA-based immunotherapies, announced new clinical results from the ongoing first-in-human Phase I trial (NCT05978102)
More news about: iLeukon Therapeutics
Nov 11, 2025, 08:40 ET INOVIO Announces Pricing of $25 Million Public Offering
PLYMOUTH MEETING, Pa., Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Nov 11, 2025, 08:32 ET Gerosynth Labs Announces Launch of Mytulin EQ, an Advanced Equine Nutritional Supplement
BLOOMINGTON, Minn., Nov. 11, 2025 /PRNewswire/ -- Gerosynth Labs, Inc., a private biotechnology company specializing in pharmaceutical preparations for oncology and regenerative health, and parent company of Mytosynth Nutraceuticals, LLC, today
More news about: Gerosynth Labs, Inc.
Nov 11, 2025, 08:31 ET EXoPERT Joins JLABS TMC, Johnson & Johnson's Global Incubator Network
EXoPERT, a biotechnology company pioneering AI-powered exosome-based liquid biopsy diagnostics for multi-cancer early detection, is excited to announce that it has joined Johnson
More news about: EXoPert
Nov 11, 2025, 08:30 ET Using a Novel Automated Immunoassay to Streamline Batch Testing, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 11, 2025, 08:30 ET Becoming a sponsor of choice for high-performing sites, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 11, 2025, 08:30 ET Exploring Polycystic Kidney Disease Clinical Trials and New Treatments, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 11, 2025, 08:00 ET CITGO Commemorates National STEM Day with Local Events and Approximately $840,000 in Grants to Schools in Illinois, Louisiana and Texas
School Region-wideWilliam Marsh Rice University - BuoyBead biotechnology kits for schools throughout Illinois, Louisiana and Texas About CITGO
More news about: CITGO Petroleum Corporation
Nov 11, 2025, 05:09 ET MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture,
More news about: MGI Tech Co., Ltd.
Nov 11, 2025, 04:40 ET MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture,
More news about: MGI Tech Co., Ltd.
Nov 10, 2025, 18:09 ET INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 18:00 ET Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan
in-licensing, acquisition, and internal discovery. The group reorganization was designed to align Onward's corporate structure with Taiwan's dynamic biotechnology capital market and to support the company's long-term growth plans, including future fundraising and potential public listing.
More news about: Onward Therapeutics
Nov 10, 2025, 17:31 ET Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight
the forecast period (2025–2034). Leading oropharyngeal cancer companies developing emerging therapies, such as PDS Biotechnology, Inovio Pharmaceuticals, MedImmune, Cue Biopharma, BioNTech, and others, are developing new therapy for oropharyngeal cancer that can be available
More news about: DelveInsight Business Research, LLP
Nov 10, 2025, 16:05 ET INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
PLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 10:50 ET ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement
10, 2025 /PRNewswire/ -- ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced they have signed a
More news about: ERS Genomics
Nov 10, 2025, 10:30 ET Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming
More news about: Anixa Biosciences, Inc.
Nov 10, 2025, 09:16 ET LPG® America and Epicutis® Partner to Redefine Professional Education with an Exclusive Webinar on Reactive Skin
/PRNewswire/ -- LPG® America, the U.S. subsidiary of LPG® Group—the global pioneer of non-invasive cellular stimulation—has partnered with Epicutis®, a biotechnology-based skincare innovator, to deliver an advanced educational webinar for licensed professionals this November.
More news about: LPG America
Nov 10, 2025, 09:12 ET Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Nov 10, 2025, 09:06 ET B. Riley Securities Strengthens Healthcare and Life Sciences Investment Banking with Senior Hire
in biopharma and life sciences, including specialty pharmaceuticals, CROs, CDMOs, tools and diagnostics – and strong relationships with leading biotechnology companies and investors. Over his career, he has advised on more than 140 transactions with combined deal value exceeding $30 billion.
More news about: B. Riley Securities
Nov 10, 2025, 09:04 ET FDA Completes Safety for Gallant's First Ready-to-Use Stem Cell Therapy for Refractory FCGS
Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced a significant advancement in the FDA's conditional approval process for
More news about: Gallant
Nov 10, 2025, 08:38 ET The DNA Company Named Functional Genomics Innovation of the Year for the 2025 BioTech Breakthrough Awards
that support their well-being." The BioTech Breakthrough Awards honor excellence and innovation in the life sciences and biotechnology industries, recognizing companies, products, and research that are driving meaningful progress in health and medical technology. This year's program
More news about: The DNA Company
Nov 10, 2025, 08:30 ET Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
Brii Biosciences Limited ("Brii Bio," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced 24-week post end of treatment
More news about: Brii Biosciences Limited
Nov 10, 2025, 08:30 ET 騰盛博藥在2025年AASLD大會上發佈ENSURE II期研究最新突破性數據，進一步強調BRII-179作為慢乙肝治癒性療法的潛力
Elebsiran是一種經皮下注射給藥的靶向乙型肝炎病毒（HBV）的小干擾核糖核酸（siRNA）研究性藥物，旨在降解HBV RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及丁型肝炎病毒（HDV）的直接抗病毒活性。其是首個進入臨床的採用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc. 獲得了在大中華地區開發和商業化elebsiran的獨家權益。2024年5月，中國國家藥品監督管理局（NMPA）藥品審評中心（CDE）授予elebsiran突破性療法認定。 關於騰盛博藥
More news about: 騰盛博藥生物科技有限公司